Physician profile
Storm M Eagle
NPI 1649607383
$7,018.95
in general payments reported to CMS, 2019-2025
43 companies · $1,752 in 2025
The $1,752 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $825 · 2022: $1,614 · 2023: $1,420 · 2024: $1,407 · 2025: $1,752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,580.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,325.80 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,276.38 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $803.44 | 2021-2025 | |
| Lilly USA, LLC | $639.40 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $431.79 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $421.56 | 2022-2025 | Jardiance |
| Paratek Pharmaceuticals, INC. | $295.57 | 2024-2025 | Nuzyra |
| Amgen INC. | $189.58 | 2023-2024 | Repatha, Otezla, Prolia |
| Phathom Pharmaceuticals, INC. | $173.17 | 2024-2025 | Voquezna |
| Optinose US, INC. | $160.67 | 2022-2025 | |
| Pfizer INC. | $140.61 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $75.30 | 2022 | |
| Hikma Pharmaceuticals USA | $74.16 | 2024-2025 | Ryaltris |
| Biohaven Pharmaceutical Holding Company LTD. | $70.96 | 2022 | |
| Dexcom, INC. | $67.66 | 2023-2025 | Dexcom G6 Transmitter |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Storm Eagle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.